Loading...
•
Dec 31, 2024
Enfusion Q4 2024 Earnings Report
Enfusion reported its financial results for the fourth quarter and full year ended December 31, 2024, with a significant increase in total revenue and adjusted EBITDA.
Key Takeaways
Enfusion, a leading SaaS provider for investment managers, announced strong financial results for Q4 2024, with total revenue increasing by 13.9% to $52.9 million and Adjusted EBITDA rising by 25.3% to $12.3 million. The company also reported an Annual Recurring Revenue (ARR) of $210.4 million, up 13.6% from the previous year, and a Net Dollar Retention Rate of 103.0%.
Total revenue for Q4 2024 increased by 13.9% year-over-year to $52.9 million.
Adjusted EBITDA grew by 25.3% to $12.3 million in Q4 2024, with an Adjusted EBITDA Margin of 23.2%.
Annual Recurring Revenue (ARR) reached $210.4 million at the end of December 2024, representing a 13.6% increase from December 2023.
The Net Dollar Retention Rate (NDR) improved to 103.0% in Q4 2024, up from 102.1% in December 2023.
Enfusion
Enfusion
Enfusion Revenue by Segment
Revenue by Segment
Platform subscriptions Revenue
CapyFin.comManaged services Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Enfusion will not be providing financial guidance for fiscal 2025 due to the pending acquisition by Clearwater Analytics. The transaction is expected to close in the second quarter of 2025, subject to shareholder and regulatory approvals.
Positive Outlook
- The transaction is anticipated to close in the second quarter of 2025.
- The acquisition by Clearwater Analytics may bring new opportunities and synergies.
- The company's strong Q4 2024 performance indicates a healthy business going into the acquisition.
- The transaction is subject to approval by Enfusion shareholders, indicating a democratic process.
- Required regulatory approvals are being sought, ensuring compliance and a smooth transition.
Challenges Ahead
- No financial guidance will be provided for fiscal 2025 due to the pending acquisition.
- The transaction is subject to shareholder approval, which is not guaranteed.
- The transaction is subject to required regulatory approvals, which could cause delays.
- Customary closing conditions must be met, which could introduce uncertainties.
- The company will not be hosting an earnings conference call or releasing a Shareholder Letter, limiting direct communication with investors.
Revenue & Expenses
Visualization of income flow from segment revenue to net income